Patients and Methods.
The study was carried out in Spain, between April 1, 2019 and January
31, 2020, coordinated by the working group on osteoporosis and mineral
metabolism of the Spanish Society of Internal Medicine (SEMI). Patients
who had previously received a minimum of one year of DMAB treatment,
injecting at least 2 doses, having produced a minimum delay of 2 months
from the moment of injection, were included. Patients must have suffered
at least one fragility fracture after discontinuation of DMAB. This
fracture was verified by a lateral radiography of the thoracic and
lumbar spine, an MRI of the entire spine, or both. Genant’s
classification (12) was applied to diagnose vertebral fracture. Those
patients with cancer, Paget’s disease of bone or when the fracture was
traumatic were excluded. The collection of clinical data was carried out
with a questionnaire designed for this purpose.